Literature DB >> 9698563

A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2.

T K Bera1, M Onda, U Brinkmann, I Pastan.   

Abstract

We have used protein engineering to generate a stable bivalent Fv molecule of the anti-erbB2 monoclonal antibody e23. The VH and VL domains of the Fv are linked to each other by a disulfide bond and the two Fvs are connected by a flexible 15 amino acid residue (Gly4-Ser)3 linker. The e23 (dsFv)2 molecule is fused to a truncated form of Pseudomonas exotoxin to generate a bivalent disulfide-stabilized, (dsFv)2, immunotoxin. The immunotoxin was expressed in Escherichia coli, refolded in vitro and purified to about 95% purity. Binding studies demonstrated that the (dsFv)2 molecule has a much higher affinity for erbB2 than a monovalent dsFv molecule and a similar binding affinity as the parental antibody e23. The (dsFv)2 immunotoxin was 5 to 20-fold more cytotoxic to two e23 antigen-positive cell lines than the monovalent dsFv immunotoxin. The bivalent dsFv molecule is very stable, retaining 94% of its activity after a 24 hours incubation in human serum at 37 degreesC. Two other molecules with shorter linkers five and ten amino acid residues in length were produced and showed similar activities as the molecule containing a 15 amino acid residue linker. The bivalency, stability and the relative ease of purification makes these e23 (dsFv)2 molecules valuable reagents for cancer immunotherapy and diagnosis. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9698563     DOI: 10.1006/jmbi.1998.1948

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   6.151


  12 in total

1.  Disulfide-stabilized single-chain antibody-targeted superantigen: construction of a prokaryotic expression system and its functional analysis.

Authors:  Jian-Li Wang; Yu-Ling Zheng; Ru Ma; Bao-Li Wang; Ai-Guang Guo; Yong-Qiang Jiang
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

2.  Homology modelling and bivalent single-chain Fv construction of anti-HepG2 single-chain immunoglobulin Fv fragments from a phage display library.

Authors:  Ming Ni; Bing Yu; Yu Huang; Zhenjie Tang; Ping Lei; Xin Shen; Wei Xin; Huifen Zhu; Guanxin Shen
Journal:  J Biosci       Date:  2008-12       Impact factor: 1.826

3.  Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.

Authors:  Y Cao; J W Marks; Z Liu; L H Cheung; W N Hittelman; M G Rosenblum
Journal:  Oncogene       Date:  2013-02-04       Impact factor: 9.867

4.  Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity.

Authors:  Junxia Wei; Tapan K Bera; Xiu Fen Liu; Qi Zhou; Masanori Onda; Mitchell Ho; Chin-Hsien Tai; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-26       Impact factor: 11.205

5.  A dual-purpose protein ligand for effective therapy and sensitive diagnosis of anthrax.

Authors:  Momchilo Vuyisich; S Gnanakaran; Julie A Lovchik; C Rick Lyons; Goutam Gupta
Journal:  Protein J       Date:  2008-08       Impact factor: 2.371

Review 6.  Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery.

Authors:  Stefan Dengl; Claudio Sustmann; Ulrich Brinkmann
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 12.988

7.  Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells.

Authors:  Jinle Tang; Jialu Li; Xuejun Zhu; Yuan Yu; Dan Chen; Lei Yuan; Zhenyang Gu; Xingding Zhang; Lin Qi; Zhishu Gong; Pengjun Jiang; Juhua Yu; Huimin Meng; Gangli An; Huyong Zheng; Lin Yang
Journal:  Oncotarget       Date:  2016-06-07

8.  SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice.

Authors:  C Kimchi-Sarfaty; W D Vieira; D Dodds; A Sherman; R J Kreitman; S Shinar; M M Gottesman
Journal:  Cancer Gene Ther       Date:  2006-02-24       Impact factor: 5.854

9.  Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.

Authors:  Rafal Zielinski; Ilya Lyakhov; Amy Jacobs; Oleg Chertov; Gabriela Kramer-Marek; Nicholas Francella; Andrew Stephen; Robert Fisher; Robert Blumenthal; Jacek Capala
Journal:  J Immunother       Date:  2009-10       Impact factor: 4.912

10.  Construction of a disulfide-stabilized diabody against fibroblast growth factor-2 and the inhibition activity in targeting breast cancer.

Authors:  Yaxiong Cai; Jinxia Zhang; Xuejun Lao; Haowu Jiang; Yunfei Yu; Yanrui Deng; Jiangchuan Zhong; Yiye Liang; Likuan Xiong; Ning Deng
Journal:  Cancer Sci       Date:  2016-07-26       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.